Pfizer Total Current Assets 2010-2024 | PFE
Pfizer total current assets from 2010 to 2024. Total current assets can be defined as the sum of all assets that are classified as current because they will provide a benefit within one year.
- Pfizer total current assets for the quarter ending September 30, 2024 were $43.223B, a 41.6% decline year-over-year.
- Pfizer total current assets for 2023 were $43.333B, a 15.46% decline from 2022.
- Pfizer total current assets for 2022 were $51.259B, a 14.13% decline from 2021.
- Pfizer total current assets for 2021 were $59.693B, a 70.23% increase from 2020.
Pfizer Annual Total Current Assets (Millions of US $) |
2023 |
$43,333 |
2022 |
$51,259 |
2021 |
$59,693 |
2020 |
$35,067 |
2019 |
$32,803 |
2018 |
$49,926 |
2017 |
$41,141 |
2016 |
$38,949 |
2015 |
$43,804 |
2014 |
$55,595 |
2013 |
$56,244 |
2012 |
$64,831 |
2011 |
$60,817 |
2010 |
$61,013 |
2009 |
$61,670 |
Pfizer Quarterly Total Current Assets (Millions of US $) |
2024-09-30 |
$43,223 |
2024-06-30 |
$37,825 |
2024-03-31 |
$42,415 |
2023-12-31 |
$43,333 |
2023-09-30 |
$74,012 |
2023-06-30 |
$73,347 |
2023-03-31 |
$50,078 |
2022-12-31 |
$51,259 |
2022-09-30 |
$70,403 |
2022-06-30 |
$67,466 |
2022-03-31 |
$54,420 |
2021-12-31 |
$59,693 |
2021-09-30 |
$57,900 |
2021-06-30 |
$48,814 |
2021-03-31 |
$39,533 |
2020-12-31 |
$35,067 |
2020-09-30 |
$47,739 |
2020-06-30 |
$46,424 |
2020-03-31 |
$34,738 |
2019-12-31 |
$32,803 |
2019-09-30 |
$33,459 |
2019-06-30 |
$47,073 |
2019-03-31 |
$45,290 |
2018-12-31 |
$49,926 |
2018-09-30 |
$41,583 |
2018-06-30 |
$37,303 |
2018-03-31 |
$34,835 |
2017-12-31 |
$41,141 |
2017-09-30 |
$40,291 |
2017-06-30 |
$36,385 |
2017-03-31 |
$35,878 |
2016-12-31 |
$38,949 |
2016-09-30 |
$38,501 |
2016-06-30 |
$43,845 |
2016-03-31 |
$41,298 |
2015-12-31 |
$43,804 |
2015-09-30 |
$45,001 |
2015-06-30 |
$51,715 |
2015-03-31 |
$49,443 |
2014-12-31 |
$55,595 |
2014-09-30 |
$56,987 |
2014-06-30 |
$58,287 |
2014-03-31 |
$57,793 |
2013-12-31 |
$56,244 |
2013-09-30 |
$59,500 |
2013-06-30 |
$61,435 |
2013-03-31 |
$64,763 |
2012-12-31 |
$64,831 |
2012-09-30 |
$57,127 |
2012-06-30 |
$58,765 |
2012-03-31 |
$54,863 |
2011-12-31 |
$60,817 |
2011-09-30 |
$62,732 |
2011-06-30 |
$60,484 |
2011-03-31 |
$58,244 |
2010-12-31 |
$61,013 |
2010-09-30 |
$54,089 |
2010-06-30 |
$51,101 |
2010-03-31 |
$49,916 |
2009-12-31 |
$61,670 |
2009-09-30 |
$73,784 |
2009-06-30 |
$71,550 |
2009-03-31 |
$54,253 |
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Large Cap Pharmaceutical |
$142.241B |
$58.496B |
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|